Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review

Basiliximab vs. Antithymocyte Globulin as Initial Induction Therapy for Lung Transplantation: A National Two Years Review

Basiliximab (BAS) is an interleukin-2 monoclonal antibody initially used as induction therapy after liver and kidney transplantation. BAS use after lung transplantation (LTx) has supplanted antithymocyte globulin (ATG) as the main induction immunosuppression over the years, but few studies have comp...

Full description

Bibliographic Details
Main Authors: Bruno Mendes, Carlos Figueiredo, Mariana Cabral, Alexandra Borba, Alexandra Mineiro, João Cardoso, Paulo Calvinho, Luísa Semedo, José Fragata
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Transplantology
Subjects:
lung
transplantation
basiliximab
antithymocyte globulin
induction
Online Access:https://www.mdpi.com/2673-3943/3/3/27

Internet

https://www.mdpi.com/2673-3943/3/3/27

Similar Items